Corporate Profile / Access
As of Apr. 1, 2024
Mitsubishi Chemical Group Corporation
Company name | Mitsubishi Chemical Group Corporation |
---|---|
Head office |
1-1 Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-8251 |
Access | ・8-minutes walk from the Marunouchi North Exit of JR Tokyo Station ・One-minute walk from Exit C13b of Otemachi Station (subway) |
Representative | Representative Corporate Executive Officer, President & Chief Executive Officer, Manabu Chikumoto |
Date of establishment | October 3, 2005 |
Paid-in capital | 50 billion yen |
Main scope of business | Management of Group companies (Development of the Group strategies and allocation of financial resource) |
Sales revenue (Consolidated) | 4,634.5 billion yen (FY2022) |
Number of employees | 68,639 (Consolidated) (As of March 31, 2023) |
Subsidiaries and affiliates | 593 (Consolidated subsidiaries:422 As of March 31, 2023) |
Listings | The Prime Market of Tokyo Stock Exchange |
Fiscal year end | March 31 |
Mitsubishi Chemical Corporation
Company name | Mitsubishi Chemical Corporation |
---|---|
Head office |
1-1 Marunouchi 1-chome, Chiyoda-ku, Tokyo 100-8251 |
Access | ・8-minutes walk from the Marunouchi North Exit of JR Tokyo Station ・One-minute walk from Exit C13b of Otemachi Station (subway) |
Representative | Representative Director, Yasuo Shimodaira Representative Director, Manabu Chikumoto |
Date of incorporation | April 1, 2017 (Date of foundation: August 31, 1933) |
Paid-in capital | 53,229 million yen |
Line of business | Performance products, industrial materials, and others |
Number of employees | 42,127 (Consolidated), 13,100 (Non-consolidated) (As of March 31, 2023) |
Shareholder | Mitsubishi Chemical Group Corporation 100% |
Mitsubishi Tanabe Pharma Corporation
Company name | Mitsubishi Tanabe Pharma Corporation |
---|---|
Head office |
2-10 Dosho-machi, 3-chome, Chuo-ku, Osaka 541-8505 |
Access | ・8-minutes walk from Exit 11 of Yodoyabashi Station on the Subway Midosuji Line. ・10-minutes walk from Exit 6 of Kitahama Station on Subway Sakaisuji Line. |
Representative | Representative Director, Akihiro Tsujimura Representative Director, Hiroaki Ueno |
Date of incorporation | October 1, 2007 |
Paid-in capital | 50 billion yen |
Line of business | Manufacture and sale of pharmaceuticals, centered on ethical drugs |
Number of employees | 6,370 (Consolidated) 3,107 (Non-consolidated)(As of March 31, 2023) |
Shareholder | Mitsubishi Chemical Group Corporation 100% |
Nippon Sanso Holdings Corporation
Company name | Nippon Sanso Holdings Corporation |
---|---|
Head office |
Toyo Bldg., 1-3-26 Koyama, Shinagawa-ku Tokyo 142-8558, Japan |
Access | ・Transit to the Tokyu Meguro Line at the JR Meguro Station and get off at the Fudomae Station.7 minutes’ walk from the Fudomae Station to our head office. |
Representative | Representative Director, President CEO Toshihiko Hamada |
Date of incorporation | July 19, 1918(Date of establishment: October 30, 1910) |
Paid-in capital | 37,344 million yen |
Line of business | Subsidiary management and group operations in industrial gas |
Number of employees | Consolidated:19,579 (As of March 31, 2023) |
Shareholder | Mitsubishi Chemical Group Corporation 50.6% |